Brief: Matinas Biopharma Provides Positive Outcomes Update On The MAT2203 Compassionate/Expanded Use Access Program

Matinas BioPharma Holdings

26/02/2024 13:18

Feb 26 (Reuters) - Matinas BioPharma Holdings Inc
 MTNB.A :
    * MATINAS BIOPHARMA PROVIDES POSITIVE OUTCOMES UPDATE ON THE
MAT2203 COMPASSIONATE/EXPANDED USE ACCESS PROGRAM, INCLUDING
MULTIPLE PATIENTS WITH COMPLETE CLINICAL RESOLUTION
    * MATINAS BIOPHARMA PROVIDES POSITIVE OUTCOMES UPDATE ON THE
MAT2203 COMPASSIONATE/EXPANDED USE ACCESS PROGRAM, INCLUDING
MULTIPLE PATIENTS WITH COMPLETE CLINICAL RESOLUTION
    * MATINAS BIOPHARMA HOLDINGS INC - A TOTAL OF 19 PATIENTS
WITH
SERIOUS/LIFE-THREATENING INVASIVE FUNGAL INFECTIONS HAVE BEEN
ENROLLED
    * MATINAS BIOPHARMA HOLDINGS INC - TREATMENT WITH MAT2203
WAS WELL
TOLERATED AND LED TO FAVORABLE CLINICAL AND RADIOLOGICAL
RESPONSE

Source text for Eikon:  ID:nGNX5chM3f 
Further company coverage:  MTNB.A 

 ((Reuters.Briefs@thomsonreuters.com;))